Harbour BioMed (HBM), a global biopharmaceutical company focused on creating new antibody-based treatments for immune system and cancer diseases, has shared an update about its ongoing partnership with AstraZeneca. The two companies first teamed up in March 2025 to work on developing new medicines.
The goal of this partnership is to create next-generation treatments, such as antibody-drug conjugates (ADCs) and T cell engagers, using the expertise of both companies.
As part of the deal, AstraZeneca will continue to choose new research projects for Harbour BioMed to work on for the next four years. AstraZeneca will also have the option to license these new treatments for further development. Harbour BioMed could receive payments for certain milestones, as well as future royalties from sales of these treatments. The financial details of the agreement remain the same as they were in March 2025.
According to Coherent Market Insights, the Biotechnology Market is expected to grow at a CAGR of 12.3% from 2025 to 2032. Currently, the market is at USD 1,034.63 Bn in 2025 and is expected to be around USD 2,330.47 Bn by 2032. Increasing prevalence of chronic diseases, new product launches, and strategies like mergers, acquisitions, and collaboration are expected to drive the global biotechnology market growth over the forecast period.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said: "We are pleased to advance our collaboration with AstraZeneca to develop next-generation biotherapeutics in oncology. Harbour BioMed has collaborated with AstraZeneca on multiple programs since 2022, and over time, the two parties have established a trusted and solid partnership. With our strong capabilities enabled by our proprietary antibody platforms, we are well positioned to support AstraZeneca in developing innovative biotherapeutics that can address significant unmet medical needs and improve patient outcomes globally."
Harbour BioMed has developed a special technology called Harbour Mice® that helps create fully human antibodies. These antibodies come in two forms: the regular type with two heavy and two light chains (H2L2), and a newer type with only a heavy chain (HCAb).
Using the HCAb antibodies, the company has created a new treatment called HBICE®, which are bispecific antibodies. These antibodies can target and kill tumors in ways that regular combination therapies can’t.
Harbour BioMed is a worldwide biopharmaceutical company that works on creating new antibody-based treatments for immune system and cancer diseases. The company is building a strong and unique lineup of potential medicines through its own research and development (R&D), partnerships with other companies to discover and develop treatments together, and by carefully acquiring other businesses.
Source:
News Room: Harbour BioMed
Company: Harbour BioMed
